Low back pain is the leading cause of disability worldwide, and lumbar disc herniation is one of its most disruptive drivers. Between 5 and 20 adults per 1,000 are affected each year, and roughly 1 to 3 percent of the population will experience a symptomatic herniated disc. For most of them, the treatment pathway is unexpectedly narrow, and the gap in the middle of that pathway is where a great deal of avoidable suffering happens.
The Two-Option Problem
Ask most patients with a contained lumbar disc herniation what their options are, and they will describe a familiar fork in the road.
On one side sits conservative care: physiotherapy, NSAIDs, activity modification, and epidural steroid injections. These approaches are low-risk and often helpful. They also share a common limitation, in that they manage symptoms rather than address the mechanical cause of nerve root compression. When the herniation itself remains unchanged, relief can be partial or temporary.
On the other side sits surgery, typically microdiscectomy. It is an effective, well-established operation with strong outcomes in appropriately selected patients. But it carries anaesthetic risk, recovery time, and the possibility of recurrence or post-surgical complications. Many patients are understandably reluctant, and many are not yet unwell enough for a surgeon to recommend it.
That leaves a large population in the middle: too symptomatic for physiotherapy alone, not ready or not eligible for the operating theatre. This therapeutic gap has persisted for decades, and it is the reason minimally invasive, image-guided interventions have drawn renewed interest from interventional radiologists and spine specialists.
How Oxygen-Ozone Chemonucleolysis Works
Intradiscal oxygen-ozone therapy sits squarely in that middle ground. The procedure involves the percutaneous, image-guided injection of a precisely calibrated oxygen-ozone gas mixture directly into the nucleus pulposus of the affected disc. It is performed under fluoroscopic or CT guidance, usually with local anaesthetic, and typically takes well under an hour.
The mechanism is mechanical rather than purely analgesic. Ozone oxidises proteoglycans within the nucleus pulposus, reducing the disc’s capacity to retain water. The nucleus dehydrates and shrinks, and that volume reduction lowers intradiscal pressure. Because the relationship between disc volume and internal pressure is non-linear, a modest reduction in volume produces a disproportionately larger drop in pressure. Modelling work by Murphy and colleagues suggests a 6 percent reduction in nucleus pulposus volume can yield close to a 10 percent reduction in pressure. The result is decompression of the irritated nerve root, and with it, relief of radicular leg pain.
Imaging data supports this mechanism. A study of 283 patients found statistically significant post-treatment volume reduction in 96.1 percent of treated discs at six months. In other words, the change is measurable, not inferred from symptom reports alone.
What the Clinical Evidence Shows
Oxygen-ozone chemonucleolysis is not new. It has been used in Europe, particularly Italy, for more than two decades. But the quality of the supporting evidence has improved considerably in recent years.
The most rigorous data point is a multicentre, non-inferiority randomised controlled trial published in The Spine Journal in 2022, comparing intradiscal oxygen-ozone chemonucleolysis directly against microdiscectomy for lumbar disc herniation radiculopathy. The trial, conducted across sites in Greece, Italy, Switzerland and Canada, found the injection non-inferior to surgery at six months, with 71 percent of patients in the ozone arm avoiding surgery altogether. The full paper is available through The Spine Journal for clinicians who want to review the methodology in detail.
Longer-horizon data is also encouraging. Follow-up research tracking patients over five and ten years reported effectiveness rates of 82 percent and 88 percent respectively among those who avoided surgery. A meta-analysis pooling roughly 8,000 patients found leg pain relief in 62.5 to 86 percent of cases, with a 79.7 percent likelihood of improvement on the modified MacNab scale.
Safety is arguably the more compelling finding. That same 8,000-patient meta-analysis reported an adverse event rate of 0.6 percent, a figure that compares favourably with essentially any surgical alternative. A separate systematic review of 2,597 patients reached similar conclusions on both safety and efficacy. For a procedure positioned as a step before surgery rather than a replacement for it, a low complication profile is not a nice-to-have. It is the entire premise.
Who Is a Candidate, and Who Is Not
This is where careful patient selection matters, and where responsible messaging around ozone therapy for herniated disc treatment becomes important.
The evidence base applies specifically to contained lumbar disc herniations, meaning cases where the annulus fibrosus remains intact and the herniated material has not sequestered. Patients with extruded or sequestered fragments, spinal instability, significant stenosis, or progressive neurological deficit are generally not appropriate candidates and may need surgical referral.
Equally important, this is a targeted intradiscal procedure performed by trained interventionalists under image guidance. It should not be conflated with the broader and far less well-supported category of systemic “ozone therapy” marketed for unrelated conditions. The clinical literature described above concerns a specific procedure, a specific anatomical target, and a specific patient population.
Cauda equina symptoms, including saddle anaesthesia, bladder or bowel dysfunction, and bilateral leg weakness, remain a surgical emergency and warrant immediate assessment rather than an elective injection.
Where the Technology Is Heading
Standardisation has historically been the field’s weak point. Ozone concentration, injection volume, and delivery technique have varied between operators and between countries, which complicates comparison across studies. Purpose-built systems that control dosing and delivery are the natural next step, and companies such as SpinaFX Medical have developed technology aimed at exactly that problem, bringing consistency and regulatory rigour to a procedure that has often been performed with improvised equipment.
Regulatory pathways vary significantly by jurisdiction, and availability differs from country to country. Patients interested in this option should discuss it with a spine specialist or interventional radiologist familiar with the technique in their region rather than assuming access.
The Bottom Line
Herniated disc care has been shaped for too long by a binary choice between conservative management that may not address the underlying compression and surgery that many patients neither want nor need. Intradiscal oxygen-ozone chemonucleolysis offers a genuine middle path: mechanically plausible, supported by randomised and long-term data, and notable for a low adverse event rate.
It will not replace microdiscectomy, and it should not. But for the substantial group of patients stranded between physiotherapy and the operating theatre, a well-selected minimally invasive option is a meaningful addition to the toolkit.
This article is intended for general information and does not constitute medical advice. Readers experiencing back or leg pain should consult a qualified healthcare professional.